Everolimus, at type of mammalian target of rapamycin (mTOR) inhibitor, is approved for the treatment of advanced renal cell carcinoma, metastatic hormone receptor-positive breast cancer, and pancreatic neuroendocrine tumors (P-NETs). This evidence concerns the gene MTOR and pancreatic neuroendocrine tumor.